NuProbe is a genomics and molecular diagnostics company with molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe's vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/11/21 | $42,000,000 |
BioTrack Capital Juming Capital Panlin Capital Ruomu Capital Serica Partners Taifu Capital Tuobang Capital Yonghua Capital | undisclosed |
